Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
BioPharma Dive2d
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.
Yahoo Finance21d
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Vertex Pharmaceuticals stock declined almost 13% in six months due to poor test results for a new drug. When it comes to the drug and biotech sector, a major pipeline setback can hit the stock ...
Yahoo Finance3d
Vertex COO Arbuckle to step down later this year
Duncan McKechnie, the company’s North America sales head, will be promoted to chief commercial officer, Vertex said Monday as part of its announcement of fourth quarter earnings. Arbuckle joined ...
Hosted on MSN21d
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...